Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination

Chemotherapy

Volumn 57, Issue 5, 2012, Pages 402-416

  Bulitta, Jurgen B ^a   Kinzig, Martina ^a   Naber, Christoph K ^b   Wagenlehner, Florian M E ^c   Sauber, Christian ^a   Landersdorfer, Cornelia B ^a   Sörgel, Fritz ^a,d   Naber, Kurt G ^e  

^a Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Urologische Klinik   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Body fluid penetration; Chronic bacterial prostatitis; Ejaculate; Pharmacokinetic drug drug interaction; Population pharmacokinetic modeling; Prostatic fluid; Sperm cells; Vaginal fluid

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BODY FLUID; CHRONIC DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG URINE LEVEL; EJACULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; SEMINAL PLASMA; SINGLE DRUG DOSE; SPERM; TISSUE DISTRIBUTION; VAGINA DISCHARGE;

ADOLESCENT; ADULT; BODY FLUIDS; CIPROFLOXACIN; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; OFLOXACIN; PROSTATE; SEMEN; SEMINAL VESICLES; TISSUE DISTRIBUTION; VAGINA; YOUNG ADULT;

EID: 80054796991     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000329520     Document Type: Article

References (96)

1. Sasabe H, Kato Y, Terasaki T, Tsuji A, Su-giyama Y: Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. Biopharm Drug Dispos 1999; 20:151-158. (Pubitemid 29137673)
2. de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, Couet W: In vitro and in vivo investigations on fluoroquinolones; effects of the p-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci 2000; 12: 85-93.
3. Zhao YL, Cai SH, Wang L, Kitaichi K, Tat-sumi Y, Nadai M, Yoshizumi H, Takagi K, Takagi K, Hasegawa T: Possible involvement of p-glycoprotein in the biliary excretion of grepafloxacin. Clin Exp Pharmacol Physiol 2002; 29: 16 7-17 2. (Pubitemid 34233970)
4. Yamaguchi H, Yano I, Saito H, Inui K: Phar-macokinetic role of p-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 2002; 300:1063-1069. (Pubitemid 34165013)
5. Ruiz-Garcia A, Lin H, Pla-Delfina JM, Hu M: Kinetic characterization of secretory transport of a new ciprofloxacin derivative (cnv97100) across caco-2 cell monolayers. J Pharm Sci 2002; 91:2511-2519. (Pubitemid 35379409)
6. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human p-glycoprotein expressed in a kidney epithelial cell line, llc-pk1. J Pharmacol Exp Ther 1997; 282: 955-960. (Pubitemid 27340200)
7. Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R: Absorption of ofloxacin isomers in the rat small intestine. Antimi-crob Agents Chemother 1997; 41:2274-2277. (Pubitemid 27422226)
8. Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R: Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process. Antimicrob Agents Chemother 1996; 40:2126-2130. (Pubitemid 26296259)
9. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y: Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoro-quinolones. Drug Metab Dispos 2007; 35: 1873-1879. (Pubitemid 47481581)
10. Kamiya A, Yamashita M, Takagi S, Arakawa S, Kamidono S: Serum concentration and renal handling of levofloxacin (DR-3355) and of loxacin in volunteers by a cross-over study. Chemotherapy 1992; 40: 196-202.
11. Yano I, Ito T, Takano M, Inui K: Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. Pharm Res 1997; 14: 508-511. (Pubitemid 27205013)
12. Sorgel F, Kinzig M: Pharmacokinetics of gy-rase inhibitors. 2. Renal and hepatic elimination pathways and drug interactions. Am J Med 1993; 94: 56S-69S. (Pubitemid 23089430)
13. Shimizu A, Miyoshi M, Sugie M, Ueyama J, Yamaguchi T, Sasaki T, Takagi K, Jin M, Miyamoto K, Tsuji A, Hasegawa T: Possible involvement of p-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol 2004; 501:151-159. (Pubitemid 39298948)
14. Matsuo Y, Yano I, Ito T, Hashimoto Y, Inui K: Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther 1998; 287:672-678. (Pubitemid 29133668)
15. Ohtomo T, Saito H, Inotsume N, Yasuhara M, Inui KI: Transport of levofloxacin in a kidney epithelial cell line, LLC-PK1: interaction with organic cation transporters in apical and basolateral membranes. J Pharmacol Exp Ther 1996; 276:1143-1148. (Pubitemid 126660590)
16. Rodriguez-Ibanez M, Sanchez-Castano G, Montalar-Montero M, Garrigues TM, Ber-mejo M, Merino V: Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepaf loxacin. Int J Pharm 2006; 307: 33-41. (Pubitemid 41773249)
17. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T, Suyama H, Doi M, Kuwabara M: Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy. Chemotherapy 2008; 54:386-394.
18. Ikawa K, Morikawa N, Sakamoto K, Ikeda K, Ohge H, Takesue Y, Sueda T: Pharmacoki-netics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Chemotherapy 2008; 54: 131-139. (Pubitemid 351448600)
19. Wagenlehner FM, Kinzig-Schippers M, Sor-gel F, Weidner W, Naber KG: Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006; 28:551-559. (Pubitemid 44779182)
20. Beal SL, Sheiner LB, Boechmann AJ: Non-mem Users Guides (version 6). Ellicott City, Icon Development Solutions, 1989-2006.
21. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sor-gel F: Systematic comparison of the population pharmacokinetics and pharmacody-namics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 20 07; 51: 2497-2507. (Pubitemid 47047329)
22. Parke J, Holford NH, Charles BG: A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29. (Pubitemid 29125558)
23. West GB, Brown JH, Enquist BJ: A general model for the origin of allometric scaling laws in biology. Science 1997; 276:122-126. (Pubitemid 27161259)
24. West GB, Brown JH, Enquist BJ: The fourth dimension of life: fractal geometry and allo-metric scaling of organisms. Science 1999; 284:1677-1679. (Pubitemid 29291379)
25. Holford NH: A size standard for pharmaco-kinetics. Clin Pharmacokinet 1996; 30:329-332.
26. Anderson BJ, Holford NH: Mechanism-based concepts of size and maturity in phar-macokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332. (Pubitemid 351738156)
27. Cockcroft DW, Gault MH: Prediction of cre-atinine clearance from serum creatinine. Nephron 1976; 16:31-41.
28. Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P: Pharmacokinetics of ciprofloxa-cin after oral and parenteral administration. Antimicrob Agents Chemother 1985; 27: 375-379. (Pubitemid 15144703)
29. Reeves DS, Bywater MJ, Holt HA, White LO: In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Che-mot her 1984; 13: 333-3 46.
30. Fish DN, Chow AT: The clinical pharmaco-kinetics of levofloxacin. Clin Pharmacoki-net 1997; 32:101-119.
31. Davies B, Morris T: Physiologic alparameters in laboratory animals and humans. Pharm Res 1993; 10:1093-1095. (Pubitemid 23211439)
32. Sanchez Navarro MD, Sayalero Marinero ML, Sanchez Navarro A: Pharmacokinetic/pharmacodynamic modelling of ciprofloxa-cin 250 mg/12 h versus 500 mg/24 h for urinary infections. J Antimicrob Chemother 2002; 50:67-72. (Pubitemid 34785256)
33. Segel IH: Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. New York, John Wiley & Sons, 1993.
34. Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Sorgel F: Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol 2008; 66: 648-659.
35. Weiss M: The relevance of residence time theory to pharmacokinetics. Eur J Clin Pharmacol 1992;43:571-579.
36. Sorgel F, Granneman GR, Stephan U, Locke C: Effect of cimetidine on the pharmacoki-netics of temafloxacin. Clin Pharmacokinet 19 92; 22(suppl 1):75-82.
37. Sudoh T, Fujimura A, Shiga T, Sasaki M, Ha-rada K, Tateishi T, Ohashi K, Ebihara A: Renal clearance of lomefloxacin is decreased by furosemide. Eur J Clin Pharmacol 1994; 46: 267-269. (Pubitemid 24137438)
38. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W: Effect of probenecid on the distribution and elimination of ciprofloxa-cin in humans. Clin Pharmacol Ther 1995; 58: 532-541.
39. Drusano GL: An overview of the pharmacology of intravenously administered cipro-f loxacin. Am J Med 1987; 82: 339-3 45.
40. Foote EF, Halstenson CE: Effects of proben-ecid and cimetidine on renal disposition of ofloxacin in rats. Antimicrob Agents Che-mother 1998; 42:456-458. (Pubitemid 28114466)
41. Nataraj B, Rao Mamidi NV, Krishna DR: Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. Clini Drug Investig 1998; 16: 259-262. (Pubitemid 28477076)
42. Rao VV, Rambhau D, Rao BR, Srinivasu P: Circadian variation in urinary excretion of ciprofloxacin after a single-dose oral administration at 1000 and 2200 hours in human subjects. Antimicrob Agents Chemother 1997; 41:1802-1804. (Pubitemid 27339891)
43. Sorgel F, Naber KG, Jaehde U, Reiter A, Seel-mann R, Sigl G: Gastrointestinal secretion of ciprofloxacin. evaluation of the charcoal model for investigations in healthy volunteers. Am J Med 1989; 87: 62S-65S. (Pubitemid 20005148)
44. Lowes S, Simmons NL: Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 2002; 135:1263-1275. (Pubitemid 34259129)
45. Griffiths NM, Hirst BH, Simmons NL: Active intestinal secretion of the fluoroquino-lone antibacterials ciprofloxacin, norfloxa-cin and pefloxacin; a common secretory pat hway? J Pharmacol Exp Ther 1994; 269: 496-502. (Pubitemid 24157313)
46. Sikri V, Pal D, Jain R, Kalyani D, Mitra AK: Cotransport of macrolide and fluoroquino-lones, a beneficial interaction reversing p-gly-coprotein eff lux. Am J Ther 2004; 11: 433-442.
47. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res 2004; 21:330-338. (Pubitemid 38221980)
48. Plaisance KI, Drusano GL, Forrest A, Busta-mante CI, Standiford HC: Effect of dose size on bioavailability of ciprofloxacin. Antimi-crob Agents Chemother 1987; 31: 956-958. (Pubitemid 17084062)
49. Sorgel F, Kinzig M: Pharmacokinetics of gy-rase inhibitors. 1. Basic chemistry and gas-trointestina l disposition. Am J Med 1993; 94: 44S-55S. (Pubitemid 23089429)
50. Aminimanizani A, Beringer P, Jelliffe R: Comparative pharmacokinetics and phar-macodynamics of the newer fluoroquino-lone antibacterials. Clin Pharmacokinet 2001; 40: 16 9-18 7.
51. Dudley MN, Ericson J, Zinner SH: Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and com-partmental pharmacokinetic models. Anti-microb Agents Chemother 1987; 31: 1782-1786. (Pubitemid 17157644)
52. Gonzalez MA, Moranchel AH, Duran S, Pi-chardo A, Magana JL, Painter B, Drusano GL: Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther 1985; 37: 633-637. (Pubitemid 15007138)
53. Gonzalez MA, Moranchel AH, Duran S, Pi-chardo A, Magana JL, Painter B, Forrest A, Drusano GL: Multiple-dose pharmacokinet-ics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother 1985; 28: 235-239. (Pubitemid 15019955)
54. Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M, Sorgel F: Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probene-cid. Br J Clin Pha rmacol 2010; 69: 16 7-17 8.
55. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA: Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation. Anti-microb Agents Chemother 2002; 46: 586-589. (Pubitemid 34087223)
56. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Nata-rajan J, Wong FA, Corrado M: Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of in-div idual dr ug clearance in patients w it h serious community-acquired infection. Antimi-crob Agents Chemother 1998; 42:1098-1104. (Pubitemid 28227904)
57. Zhang J, Xu JF, Liu YB, Xiao ZK, Huang JA, Si B, Sun SH, Xia QM, Wu XJ, Cao GY, Shi YG, Zhang YY: Population pharmacokinet-ics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Che-mother 2009; 15: 293-300.
58. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL: Population pharmacokinetics of levofloxacin, gati-floxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-857. (Pubitemid 351358362)
59. Verho M, Korn A, Badian M, Malerczyk V, Waldhausl W: Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor. Chemotherapy 1988; 34: 170-17 7.
60. Schuck EL, Dalhoff A, Stass H, Derendorf H: Pharmacokinetic/ pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection 2005; 33(suppl 2):22-28.
61. Nix DE, Cumbo TJ, Kuritzky P, DeVito JM, Schentag JJ: Oral ciprofloxacin in the treatment of serious soft tissue and bone infections: efficacy, safety, and pharmacokinetics. Am J Med 1987; 82: 14 6-1 5 3.
62. Gobernado M, Valdes L, Alos JI, Garcia-Rey C, Dal-Re R, Garcia-de-Lomas J: Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: age-related dif fer-ences. Rev Esp Quimioter 2007; 20:206-210. (Pubitemid 47326189)
63. Arreguin V, Cebada M, Simon JI, Sifuentes-Osornio J, Bobadilla-del Valle M, Macias AE: Microbiology of urinary tract infections in ambulatory patients: therapeutic options in times of high antibiotic resistance. Rev Invest Clin 2007; 59: 239-245. (Pubitemid 350090362)
64. Wagenlehner FM, Niemetz AH, Weidner W, Naber KG: Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994-2005. Int J Antimicrob Agents 2008; 3 1 (s u p p l 1): S2 5-S3 4.
65. Hoshino K, Sato K, Akahane K, Yoshida A, Hayakawa I, Sato M, Une T, Osada Y: Significance of the methyl group on the oxazine ring of of loxacin derivatives in the inhibition of bacterial and mammalian type II topoi-somerases. Antimicrob Agents Chemother 1991; 35: 309-312.
66. Blanche F, Cameron B, Bernard FX, Maton L, Manse B, Ferrero L, Ratet N, Lecoq C, Goniot A, Bisch D, Crouzet J: Differential behaviors of staphylococcus aureus and Escherichia coli type II DNA topoisomer-ases. Antimicrob Agents Chemother 1996; 40:2714-2720. (Pubitemid 26404331)
67. A kasa k a T, Tana k a M, Yamag uch i A, Sato K: Type II topoisomerase mutations in fluoro-quinolone-resistant clinical strains of pseu-domonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001; 45:2263-2268. (Pubitemid 32664465)
68. Dalhoff A, Aigner KR, Eickenberg HU: Penetration activities of ciprofloxacin into muscle, skin and fat following oral administration. Chemioterapia 1987; 6:294-295.
69. Dalhoff A, Weuta H: Penetration of cipro-floxacin into gynecologic tissues. Am J Med 1987; 82: 133-138.
70. Barza M: Pharmacokinetics and efficacy of the new quinolones in infections of the eye, ear, nose, and throat. Rev Infect Dis 1988; 10(suppl 1):S241-S247.
71. Sorgel F, Jaehde U, Naber K, Stephan U: Pharmacokinetic disposition of quinolones i n hu ma n body f luid s and t issue s. Cl i n Pha r-macok inet 1989; 16 (s u p p l 1): 5-2 4. (Pubitemid 19112890)
72. Gerding DN, Hitt JA: Tissue penetration of the new quinolones in humans. Rev Infect Dis 1989; 11(suppl 5): S10 46-S10 57.
73. Wagenlehner FM, Naber KG: Fluoroquino-lone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. Curr Urol Rep 2004; 5:309-316.
74. Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M, Jones RN: Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis 2004; 38:1513-1520. (Pubitemid 38738543)
75. Naber KG: Role of quinolones in treatment of chronic bacterial prostatitis; in Hooper DC, Wolfson JSO (eds): Quinolone Antimicrobial Agents. Washington, American Society for Microbiology, 1993, pp 285-297.
76. Naber KG, Sorgel F, Kees F, Schumacher H, Metz R, Grobecker H: In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. J Antimicrob Chemother 1988; 22(suppl D):199-207. (Pubitemid 18264855)
77. Naber KG, Sorgel F, Kinzig M, Weigel DM: Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg. J Urol 1993; 150:1718-1721. (Pubitemid 24346933)
78. Naber KG, Sörgel F, Kinzig M, Weigel DE: Pharmakokinetik und penetration von tazo-bactam/piperacillin (tazobact) in das prosta-tasekret und das prostataadenomgewebe bei älteren patienten. Fortschr Antimikrob An-tineoplas Chemother 1992; 11:457-463.
79. Naber KG, Kinzig M, Adam D, Sorgel F, Ba-jorski AH, Kiehn R: Concentrations of cef-podoxime in plasma, ejaculate and in pros-tatic fluid and adenoma tissue. Infection 19 91; 19: 30-35.
80. Naber KG, Kinzig M, Sorgel F, Weigel D: Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection 1993; 21:98-100. (Pubitemid 23112596)
81. Naber CK, Steghafner M, Kinzig-Schippers M, Sauber C, Sorgel F, Stahlberg HJ, Naber KG: Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother 2001; 45:293-297. (Pubitemid 32039129)
82. Drusano GL: Antimicrobial pharmacody-namics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300. (Pubitemid 39490099)
83. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86. (Pubitemid 44968990)
84. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O: Tissue concentrations: do we ever learn? J Antimi-crob Chemother 2008; 61: 235-237.
85. Naber KG, Sorgel F: Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003; 35: 331-335. (Pubitemid 37363528)
86. Nasu Y, Nishitani Y, Yamada D, Hayata S, Tsugawa M, Kishi M, Mizuno A, Kumon H, Ohmori H, Nanba K: Prostatic tissue and fluid levels of lomefloxacin (NY-198). Hin-yokika kiyo 1989; 35: 551-556. (Pubitemid 19103855)
87. Suzuki K, Horiba M, Naide Y, Shinoda M, Hibi H: Clinical and bacteriological study of sparfloxacin on bacterial prostatitis (in Japanese). Hinyokika Kiyo 1992; 38:121-128.
88. Drusano GL, Preston SL, Van Guilder M, North D, Gombert M, Oefelein M, Boccu-mini L, Weisinger B, Corrado M, Kahn J: A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44: 2046-2051. (Pubitemid 30484425)
89. Lugg J, Lettieri J, Stass H, Agarwal V: Determination of the concentration of ciprofloxa-cin in prostate tissue following administration of a single, 1000 mg, extended-release dose. J Chemother 2008; 20:213-218. (Pubitemid 351797062)
90. Naber KG, Sörgel F: Antibiotic therapy: rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. A ndrolog ia 2003; 35: 331-335. (Pubitemid 37363528)
91. Naber KG, Wagenlehner FM: Clinical usefulness of levofloxacin for the treatment of urinary tract infections. Tokyo, Biomedis International, 2005, pp 26-32.
92. Naber KG: Management of bacterial prosta-titis: what's new? BJU Int 2008; 101(suppl 3):7-10. (Pubitemid 351328800)
93. Naber KG, Roscher K, Botto H, Schaefer V: Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2008; 32:145-153.
94. Naber KG: Levofloxacin and its effective use in the management of bacterial prostatitis. Penetration 2009:21-26.
95. Weidner W, Wagenlehner FM, Naber KG: Chronic bacterial prostatitis; in Shoskes DA (ed): Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Totowa, Humana Press, 2008, pp 31-43.
96. Wagenlehner FM, Kinzig-Schippers M, Sör-ge l F, Weid ner W, Na b er KG: C onc ent rat ions in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006; 28:551-559. (Pubitemid 44779182)